Albany, NY -- (SBWire) -- 08/28/2019 --Chemotherapy Induced Nausea and Vomiting Market Insights, Epidemiology and Market Forecast-2028

1. About 4.4%, 7.8% and 13.8% patients who had undergone chemotherapy experienced a Chemotherapy Induced Nausea and Vomiting event with their initial single-day Low Emetogenic Chemotherapy (LEC), Moderate Emetogenic Chemotherapy (MEC), or High Emetogenic Chemotherapy (HEC) administration, respectively in United States during the study period.
2. Around 52.4 % of patients had at least one episode of nausea or vomiting. The majority of patients received highly emetogenic chemotherapeutic regimens (69.4 %) and 77.7 % of patients received antiemetic drugs.
3. The female sex and history of motion or morning sickness are clear risk factors for nausea and vomiting.

DelveInsight launched a new report on Chemotherapy Induced Nausea and Vomiting Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Chemotherapy Induced Nausea and Vomiting market report covers a descriptive overview and comprehensive insight of the Chemotherapy Induced Nausea and Vomiting epidemiology and Chemotherapy Induced Nausea and Vomiting market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chemotherapy Induced Nausea and Vomiting market report provides insights on the current and emerging therapies.
3. Chemotherapy Induced Nausea and Vomiting market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chemotherapy Induced Nausea and Vomiting market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chemotherapy Induced Nausea and Vomiting market.

Request for sample pages

"20% of cancer patients suffer from moderate-to- severe chemotherapy-induced nausea and vomiting."

Chemotherapy Induced Nausea and Vomiting, presenting itself as one of the most distressing adverse effect of chemotherapy, is one of the main factor for the discontinuation of the chemotherapy cycles leading to poor patient compliance. Despite the fact that a complete understanding of the pathophysiology is yet to be achieved, gastrointestinal tract and Chemo trigger Zones are the two major pathways which have been identified as major drug targets to be used for the management of Chemotherapy Induced Nausea and Vomiting.
Chemotherapy Induced Nausea and Vomiting was mainly managed by the use of dopamine receptor antagonists. However, the scenario has changed drastically over the last few decades and the current therapeutic landscape can be primarily segmented based on the receptor antagonists which target various pathways of the process such as 5-HT3 receptor antagonists which include Zofran, the first FDA approved 5-HT3 antagonist, Sancuso, Aloxi, NK1 receptor antagonists such as Emend, Varubi , Ivemend Cinvanti, Rolapitant and Corticosteroids, which although not approved by the FDA for Chemotherapy Induced Nausea and Vomiting & have been found to be beneficial when used alone for the prevention of nausea and vomiting in patients receiving low emetogenic chemotherapy. Apart from these, the market can also be segmented on the basis of routes of administration, i.e., Oral and IV (Intravenous). Additionally, Heron Therapeutics has developed akynzeo as a combination therapy. It is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists for the prevention of nausea and vomiting after cancer chemotherapy.
Overall, the rise in cancer patient population, increased funding by governmental bodies and vigorous R&D activities are further expected to propel the Chemotherapy Induced Nausea and Vomiting market during the forecast period (2019-2028).

The launch of the emerging therapies is expected to significantly impact Chemotherapy Induced Nausea and Vomiting treatment scenario in the upcoming years:-
Drugs covered
1. APD403
2. Netupitant
And many others

The key players in Chemotherapy Induced Nausea and Vomiting market are:
1. Helsinn Healthcare
2. Acacia Pharma
And many others

Table of contents

1. Report Introduction
2. Chemotherapy induced Nausea and Vomiting Market Overview at a Glance
3. Chemotherapy induced Nausea and Vomiting Disease Background and Overview
4. Chemotherapy induced Nausea and Vomiting Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Chemotherapy induced Nausea and Vomiting Geography wise Incident cases
4.3. United States
4.4. EU-5
4.4.1. Assumptions and Rationale
4.4.2. Germany
4.4.3. Italy
4.4.4. Spain
4.4.5. France
4.4.6. United Kingdom
4.5. Japan
5. Chemotherapy induced Nausea and Vomiting Treatments & Medical Practices
6. Chemotherapy induced Nausea and Vomiting Marketed Products
6.1. Heron Therapeutics: Akynzeo
7. Key Emerging Therapies
7.1. Key Cross Competition
7.2. APD403: Acacia Pharma
7.3. Netupitant: Helsinn Healthcare
8. Chemotherapy induced Nausea and Vomiting Market Size
9. 7MM Chemotherapy induced Nausea and Vomiting Country-Wise Market Analysis
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Market Drivers
11. Market Barriers
12. Appendix
13. Chemotherapy induced Nausea and Vomiting Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight